{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"Count of participants with Adverse events (AEs) that are CTCAE Grade 3 or worse.\n\nPlease refer to the adverse event reporting for more detail.","groups":[{"description":"Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC\n\nPlacebo: Given IV","id":"OG000","title":"Arm I Gem+Doce+Placebo"},{"description":"Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nBevacizumab: Given IV\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC","id":"OG001","title":"Arm II Gem+Doce+Bev"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Frequency and Severity of Adverse Effects as Assessed by the CTCAE Version 4.0","type":"SECONDARY","unitOfMeasure":"Participants"}